We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.23 | 0.77% | 30.25 | 30.15 | 30.26 | 30.28 | 30.07 | 30.10 | 2,908,982 | 22:20:00 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Roche Holdings AG's (ROG.EB) Genentech unit on Friday said a Phase 3 study of Tecentriq as an adjuvant monotherapy treatment missed its primary endpoint of disease-free survival in people with muscle-invasive urothelial cancer.
The company said safety for Tecentriq appeared consistent with the known safety profile of the immunotherapy drug, with no new safety signals identified.
"Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we were not able to significantly prolong disease-free survival," Genentech said.
Genentech is conducting an extensive development program for Tecentriq, including ongoing and planned Phase 3 studies across bladder, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 24, 2020 07:37 ET (12:37 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
